Aberrations in temporal dynamics of cognitive processing induced by Parkinson's disease and Levodopa. 2023

Mohammad Mahdi Kiani, and Mohammad Hossein Heidari Beni, and Hamid Aghajan
Department of Electrical Engineering, Sharif University of Technology, Tehran, Iran.

The motor symptoms of Parkinson's disease (PD) have been shown to significantly improve by Levodopa. However, despite the widespread adoption of Levodopa as a standard pharmaceutical drug for the treatment of PD, cognitive impairments linked to PD do not show visible improvement with Levodopa treatment. Furthermore, the neuronal and network mechanisms behind the PD-induced cognitive impairments are not clearly understood. In this work, we aim to explain these cognitive impairments, as well as the ones exacerbated by Levodopa, through examining the differential dynamic patterns of the phase-amplitude coupling (PAC) during cognitive functions. EEG data recorded in an auditory oddball task performed by a cohort consisting of controls and a group of PD patients during both on and off periods of Levodopa treatment were analyzed to derive the temporal dynamics of the PAC across the brain. We observed distinguishing patterns in the PAC dynamics, as an indicator of information binding, which can explain the slower cognitive processing associated with PD in the form of a latency in the PAC peak time. Thus, considering the high-level connections between the hippocampus, the posterior and prefrontal cortices established through the dorsal and ventral striatum acting as a modulatory system, we posit that the primary issue with cognitive impairments of PD, as well as Levodopa's cognitive deficit side effects, can be attributed to the changes in temporal dynamics of dopamine release influencing the modulatory function of the striatum.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D003071 Cognition Intellectual or mental process whereby an organism obtains knowledge. Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson

Related Publications

Mohammad Mahdi Kiani, and Mohammad Hossein Heidari Beni, and Hamid Aghajan
December 2011, Journal of neurology,
Mohammad Mahdi Kiani, and Mohammad Hossein Heidari Beni, and Hamid Aghajan
January 2006, Revista de neurologia,
Mohammad Mahdi Kiani, and Mohammad Hossein Heidari Beni, and Hamid Aghajan
March 2005, Journal of neural transmission (Vienna, Austria : 1996),
Mohammad Mahdi Kiani, and Mohammad Hossein Heidari Beni, and Hamid Aghajan
January 2007, Handbook of clinical neurology,
Mohammad Mahdi Kiani, and Mohammad Hossein Heidari Beni, and Hamid Aghajan
July 2003, Acta neurologica Scandinavica,
Mohammad Mahdi Kiani, and Mohammad Hossein Heidari Beni, and Hamid Aghajan
July 1987, Rinsho shinkeigaku = Clinical neurology,
Mohammad Mahdi Kiani, and Mohammad Hossein Heidari Beni, and Hamid Aghajan
June 1996, Neurology,
Mohammad Mahdi Kiani, and Mohammad Hossein Heidari Beni, and Hamid Aghajan
January 2008, Neuropsychologia,
Mohammad Mahdi Kiani, and Mohammad Hossein Heidari Beni, and Hamid Aghajan
January 2016, Frontiers in psychology,
Mohammad Mahdi Kiani, and Mohammad Hossein Heidari Beni, and Hamid Aghajan
June 2016, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
Copied contents to your clipboard!